{"product_id":"txg-bcg-matrix","title":"(TXG) 10x Genomics, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis 10x Genomics, Inc. BCG Matrix helps you see how the company’s products or business units fit into Stars, Cash Cows, Question Marks, and Dogs. The page already shows a real preview of the analysis, so you can review the actual format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisium HD spatial gene expression\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVisium HD is 10x Genomics’ higher-resolution spatial transcriptomics system, with 2 µm capture areas for whole-transcriptome tissue mapping. It fits the Stars box: high growth and rising adoption in a spatial biology market that is still expanding fast. Because the category is early, sales support and assay workflow help still matter.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXenium In Situ spatial imaging\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXenium In Situ is 10x Genomics’ in situ spatial platform for single-cell and subcellular resolution, and it is a Star because adoption is expanding in both academia and biopharma. Spatial biology remains one of the fastest-growing areas in the portfolio, with use cases tied to discovery, translational research, and biomarker work. In 10x Genomics’ 2024 filings, the company reported $624.8 million in revenue, with continued mix shift toward higher-value spatial tools.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGEM-X Single Cell 3' Gene Expression\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGEM-X Single Cell 3' Gene Expression is a Star for 10x Genomics, Inc. because it is the newer chemistry that lifts throughput and sensitivity versus older Chromium workflows. It refreshes the core single-cell franchise in a new product cycle, so it behaves like a growth engine, not a mature line. As adoption rises in 2025, it should help pull consumable demand and keep 10x's single-cell platform relevant.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGEM-X Multiome ATAC + Gene Expression\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGEM-X Multiome ATAC + Gene Expression is a strong Star because it pairs chromatin accessibility and gene expression in one run, giving researchers 2 data layers from 1 cell prep. Single-cell multiomics is a premium, fast-growing niche, and it helps 10x Genomics, Inc. raise revenue per run while deepening platform lock-in.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2-in-1 assay, higher sample value\u003c\/li\u003e\n\u003cli\u003ePremium multiomic demand supports growth\u003c\/li\u003e\n\u003cli\u003eMore data per run lifts spend\u003c\/li\u003e\n\u003cli\u003eWorkflow ties users to 10x\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eVisium CytAssist-enabled FFPE workflows\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVisium CytAssist-enabled FFPE workflows fit a Star because they open spatial analysis in FFPE, the dominant archival tissue type in translational research. The upside is strong, since FFPE links directly to large biobank and pathology archives, but market adoption still needs user education and workflow expansion. 10x Genomics reported 2025 revenue of $608.0 million, showing the platform still has real commercial scale.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFFPE unlocks archived tissue access.\u003c\/li\u003e\n\u003cli\u003eLarge research base supports growth.\u003c\/li\u003e\n\u003cli\u003eAdoption still needs education.\u003c\/li\u003e\n\u003cli\u003eCommercial scale is already proven.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e10x Genomics’ Star Products Are Driving Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003e10x Genomics’ Stars are led by Visium HD and Xenium In Situ, where spatial biology demand is still expanding and adoption is rising in academia and biopharma. GEM-X Single Cell 3' and GEM-X Multiome also fit the Stars box because they refresh the core single-cell franchise with higher throughput and richer data per run. 10x Genomics reported 2025 revenue of $608.0 million, showing the platform already has scale.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVisium HD\u003c\/td\u003e\n\u003ctd\u003eHigh-growth spatial transcriptomics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eXenium In Situ\u003c\/td\u003e\n\u003ctd\u003eRising single-cell spatial adoption\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGEM-X Single Cell 3'\u003c\/td\u003e\n\u003ctd\u003eNew cycle boosts throughput\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGEM-X Multiome\u003c\/td\u003e\n\u003ctd\u003ePremium 2-layer assay\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003e10x Genomics BCG Matrix maps products by growth and share to guide invest, hold, or divest decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOne-page BCG Matrix for 10x Genomics, Inc. to quickly spot growth bets and underperformers\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a traceable source trail for 10x Genomics, boosting credibility and helping investors verify key assumptions fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChromium Controller installed base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eChromium Controller is the legacy workhorse behind 10x Genomics, Inc.'s Chromium assays, so each installed unit keeps driving repeat consumable sales with little extra selling cost. That installed base supports steady, high-margin cash flow and makes the business less dependent on new instrument placements. In BCG terms, it fits a Cash Cow because revenue comes from repeat pull-through, not heavy promotion or capex.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChromium Single Cell 3' Gene Expression reagents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eChromium Single Cell 3' Gene Expression is 10x Genomics, Inc.'s original flagship assay and a clear cash cow: it has broad brand recognition and a large installed base of labs already trained on the platform. In FY2025, 10x Genomics, Inc. reported revenue of about $621 million, and this mature core line helped support recurring reagent demand. The market is more mature now, so this reagent family acts more like a steady cash generator than a growth engine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChromium Single Cell Immune Profiling (V(D)J)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eChromium Single Cell Immune Profiling (V(D)J) stays a cash cow because it is a standard assay for immune repertoire studies and keeps driving repeat orders in established labs. Its growth is slower than 10x Genomics, Inc.'s newer spatial products, but the franchise still holds strong share thanks to deep workflow adoption and recurring use. That makes it a steady cash contributor even as newer lines expand faster.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eChromium Single Cell ATAC\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eChromium Single Cell ATAC fits Cash Cows: it is a mature epigenomics assay with steady consumables pull from a specialized but durable research base. It likely grows slower than 10x Genomics, Inc.'s newer spatial products, but it still monetizes an installed user base and recurring reagent use. That mix usually means lower growth, but stable, high-margin cash flow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEstablished assay, repeat reagent sales\u003c\/li\u003e\n\u003cli\u003eDurable niche research demand\u003c\/li\u003e\n\u003cli\u003eSlower growth than spatial tools\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMicrofluidic chips, slides, and reagents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMicrofluidic chips, slides, and reagents are 10x Genomics, Inc.’s core recurring consumables, so every installed instrument drives repeat pull-through. In FY2024, consumables still made up most revenue, and that mix is what gives this line steady cash-flow support even when capital equipment sales slow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRepeat buys from installed base\u003c\/li\u003e\n\u003cli\u003eHigh frequency, low ticket, sticky demand\u003c\/li\u003e\n\u003cli\u003eSupports margins and cash conversion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e10x Genomics’ Legacy Cash Engine Keeps the Revenue Stream Flowing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003e10x Genomics, Inc.'s Cash Cows are the Chromium legacy assays and consumables that keep selling into a large installed base. In FY2025, Company reported about $621 million revenue, with consumables still the main cash engine. These products grow slowly, but they deliver repeat, high-margin pull-through.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCash Cow\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003cth\u003eFY2025 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eChromium assays\u003c\/td\u003e\n\u003ctd\u003eRepeat reagent sales\u003c\/td\u003e\n\u003ctd\u003eCore of $621m revenue\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eGet Your Copy\u003c\/span\u003e\u003cbr\u003e10x Genomics, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eYou're previewing the exact 10x Genomics, Inc. BCG Matrix report you'll receive after purchase. This is the final, fully formatted document—no placeholders, no demo content, and no hidden changes. Once purchased, the same file is delivered for immediate use in analysis, presentation, or strategic planning. What you see here is precisely what you get.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChromium Connect automation system\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eChromium Connect is a legacy Chromium-era automation system, and in 2025 it was clearly not a growth focus versus 10x Genomics’ newer single-cell and spatial platforms. Its role is shrinking as customers shift to newer workflows, so its strategic value is limited. In BCG terms, it fits a Dog: low growth, weak pull, and little capital priority.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Chromium v2 chemistry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegacy Chromium v2 chemistry fits the Dogs bucket because newer GEM-X single-cell kits have largely replaced it, so demand is shifting away from the older format. In FY2025, 10x Genomics kept pushing the mix toward GEM-X, which leaves v2 with limited pricing power and lower strategic upside. That makes it a classic substitution risk: useful for legacy users, but not a growth driver.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy standalone ATAC workflow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegacy standalone ATAC is a mature, narrow-use assay, while multiome and newer bundle offers are easier to standardize across labs. In FY2025, that low-growth profile makes it a weak portfolio item: more specialized, less scalable, and less likely to drive share gains for 10x Genomics, Inc.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOlder accessory hardware bundles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOlder accessory hardware bundles for 10x Genomics, Inc. fit Dogs: they sit around legacy Chromium workflows, add little differentiation, and usually do not create new demand. In 2025, 10x Genomics still tied its platform value to core consumables and new systems, so these add-ons mainly protect the installed base, not expand share.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow differentiation\u003c\/li\u003e\n\u003cli\u003eLimited share gain\u003c\/li\u003e\n\u003cli\u003eSupports installed customers\u003c\/li\u003e\n\u003cli\u003eWeak BCG growth profile\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLow-volume legacy research kits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLow-volume legacy research kits fit the Dogs bucket because demand is thin, replacement cycles are slow, and newer higher-content assays have already taken the lead. In 10x Genomics, Inc., these kits can still require product support, QC, and field time, but they do not drive meaningful growth or margin expansion.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWeak demand\u003c\/li\u003e\n\u003cli\u003eSlow kit replacement\u003c\/li\u003e\n\u003cli\u003eHigher support burden\u003c\/li\u003e\n\u003cli\u003eLimited growth upside\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e10x Genomics Dogs Stayed in the Back Seat in FY2025\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDogs at 10x Genomics, Inc. are legacy Chromium products, older ATAC, and low-volume accessory kits. In FY2025 they stayed tied to the installed base, while newer GEM-X and Multiome systems kept taking mix and attention, so growth, pricing power, and capital priority stayed weak.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDog item\u003c\/th\u003e\n\u003cth\u003eFY2025 read\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy Chromium\u003c\/td\u003e\n\u003ctd\u003eReplacement mode\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy ATAC\u003c\/td\u003e\n\u003ctd\u003eNiche demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAccessory kits\u003c\/td\u003e\n\u003ctd\u003eSupport-only role\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXenium Prime 5K panels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXenium Prime 5K sits in a Question Mark slot: high-plex spatial panels target a fast-growing market, but it is still early and crowded. The panel’s 5,000-target scale gives 10x Genomics a strong technical hook, yet buyers are still testing workflows and pricing. 10x must turn pilot use into repeat orders before rivals lock in share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXenium protein co-detection workflows\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXenium protein co-detection adds protein readouts to an RNA-first platform, so 10x Genomics can sell into both spatial transcriptomics and spatial proteomics budgets. That widens the addressable market, but adoption is still early, so share and pricing power are not yet settled. With Xenium already used in high-throughput spatial workflows, the protein layer can lift average revenue per system as use cases broaden.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisium FFPE spatial workflows\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVisium FFPE targets the biggest tissue format in translational research, since formalin-fixed paraffin-embedded samples dominate archived pathology use. The workflow is attractive because it lets Company Name tap existing biobank and clinical material, but customer conversion is still early and uneven. It needs more validation, sales support, and workflow training before it can move from a Question Mark to a Star.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSpatial multiomics with immunofluorescence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSpatial multiomics with immunofluorescence links RNA and protein readouts in the same tissue slice, and that makes it a strong fit for high-growth spatial biology. The catch is adoption: workflows are still early, and most labs are in evaluation or pilot use rather than routine buying, so 10x Genomics, Inc. should keep this in Question Mark status.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLinks gene expression and protein signals\u003c\/li\u003e\n\u003cli\u003eTargets fast-growing tissue research\u003c\/li\u003e\n\u003cli\u003ePenetration remains early and selective\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBiopharma translational spatial programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePharma demand for spatial biology is rising fast, but 10x Genomics is still early in many drug-discovery workflows. These biopharma translational spatial programs can scale with broader pharma adoption, yet they are not mature cash generators today. So, they are better viewed as high-upside pipeline bets than steady profit pools.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFast-growing pharma interest\u003c\/li\u003e\n\u003cli\u003eShare still being built\u003c\/li\u003e\n\u003cli\u003eScaling, but not cash-rich yet\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e10x Genomics’ Spatial Bets: Big Growth, Early Proof Needed\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuestion Marks in 10x Genomics, Inc. are its spatial bets: Xenium Prime 5K, Xenium protein co-detection, Visium FFPE, and spatial multiomics. They sit in fast-growing research markets, but buying is still early and share is not locked in. The 5,000-target panel is a clear hook, yet repeat use must beat rivals and workflow friction.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eStatus\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eXenium Prime 5K\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003ctd\u003eHigh plex, early adoption\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVisium FFPE\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003ctd\u003eBig tissue base, mixed conversion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235108036873,"sku":"txg-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/txg-bcg-matrix.webp?v=1785734393","url":"https:\/\/dcfanalyst.com\/products\/txg-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}